Q2
CNSY — Q2 2026 Financial Report Analysis
Cerenome (formerly Plus Therapeutics) lost $9.0M in Q2 2026 as operating costs tripled to $9.5M to build its CNSide diagnostics business, while grant revenue fell 70% and cash of $8.6M covered only about four months of burn.